P1 · PANEL / ROI / AXIS GROUND TRUTH
原 EXE 对齐基准真值复核
所有保存均写入追加式审计事件;旧标注、旧比较和旧提取结果不会被删除或覆盖。
artifact_risk
invalid_panel_split
PMID 42282892
Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 Study.
F2 · Panel A · progression-free survival
Fig. 2. Kaplan–Meier survival curve and subgroup analysis of BICR-assessed progression-free survival, showing the progression-free survival benefits with serplulimab plus chemotherapy compared to chemotherapy alone in the intent-to-treat population and across subgroups. (A) In the ITT population. The median PFS was 12.0 (95% CI 8.7 to 13.9) months in group A, 11.0 (95% CI 8.4 to 12.7) months in group B, and 5.7 (95% CI 4.9 to 6.9) in group C. Serplulimab plus chemotherapy significantly improved PFS compared with chemotherapy alone with an HR of 0.54 (95% CI 0.43 to 0.68; P < 0.001). The addition of HLX04 did not translate to an improvement in PFS compared with serplulimab plus chemotherapy (HR = 1.02, 95% CI 0.80 to 1.28; P = 0.896). (B) Exploratory subgroup analysis of PFS in group B vs. group C, suggesting a PFS benefit with serplulimab plus chemotherapy over chemotherapy alone across the various patient subgroups. (C) Exploratory subgroup analysis of PFS in group A vs. group B, implying a lack of PFS benefit with HLX04 and serplulimab plus chemotherapy over serplulimab plus chemotherapy across the various patient subgroups. Group A, serplulimab plus HLX04 and chemotherapy; Group B, serplulimab plus HLX04 placebo and chemotherapy; Group C, serplulimab placebo plus HLX04 placebo and chemotherapy. Abbreviations: BICR, blinded independent central review; CI, confidence interval; CPS, combined positive score; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; ITT, intent-to-treat; NE, not evaluable; NR, not reached; PD-L1, programmed cell death ligand 1; PFS, progression-free survival; TPS, tumor proportion score.坐标框复核
洋红 = 当前 Linux 候选;绿色 = 已保存人工真值。没有绿色框表示仍未形成真值。
当前候选 {'x0': 60, 'y0': 60, 'x1': 712, 'y1': 682}
人工真值 未保存
查看候选 OCR 与警告(只能作种子,不能自证真值)
{
"complete": false,
"engine": "RapidOCR",
"plot_bottom": 751,
"plot_left": 1,
"plot_right": 749,
"plot_top": 364,
"warnings": [
"insufficient_x_ticks",
"insufficient_y_ticks"
],
"x_axis_y": 751,
"x_confidence": 0.0,
"x_detected": false,
"x_max": null,
"x_min": null,
"x_ticks": [],
"y_axis_x": 1,
"y_confidence": 0.0,
"y_detected": false,
"y_max": null,
"y_min": null,
"y_ticks": []
}
追加一条审查结论
选择“有效 KM”时,四边 ROI、四个坐标范围、Panel、终点和曲线数均为必填。
追加式审计历史
最新事件仅作为当前缓存;以下每一条既往结论都永久保留。
| 事件 | 时间 / 审查人 | 状态 | ROI | 坐标 | 说明 |
|---|---|---|---|---|---|
| #86p1-visual-axis-audit-v2 · frozen benchmark contact sheets + original images + RapidOCR re-audit | 2026-07-28T15:12:18+00:00Codex-assisted visual audit | invalid_panel_split | - |
- |
同一裁剪同时含 KM Panel A 与森林图 Panel B,需拆分后另行纳入。 |
| #3p1-visual-audit-v1 · direct_original_image_review | 2026-07-24T17:30:14+00:00Codex P1 visual audit 2026-07-25 | invalid_panel_split | - |
- |
当前 Panel 资产同时包含上方 A 的三曲线 PFS 图和下方 B 的亚组森林图;必须先重新分割为独立 Panel A,现有整图不得作为单一 KM Panel 真值。图像 SHA-256: 7dbd6c6b5b2116e50d7cba13338c43104268bf7a80261771d9d17ae814d7e97e。 |
最近一次正式比较
Suite #3 · 2026-07-28T15:15:12+00:00
真值完整 117 / 120;通过 0;缺真值 0;无效案例 3。



